Richard Liang, Ph.D Email & Phone Number

New York, Ny, Us

As a principal founder of Dimensional Rxolution, I have established this organization specializing in preclinical discovery and development for human disease therapies. My team offers data-driven solutions tailored to our client's drug development and in-vitro diagnostics needs. The screening funnels include disease modeling, target/pathway biology investigation, toxicity assessment, in vitro/ex vivo/in vivo biomolecular assay development, target selection, lead optimization, drug delivery optimization, in vivo efficacy research, biomarker discovery, and patient stratification strategy. We also provide consultations for setting up state-of-the-art research environments, encompassing cell culture, animal vivarium, and automated screening systems for mid to ultra-high throughput. - Leadership in Business Development: Successfully acquired and managed key client relationships within the first quarter, leading to an expansion of the company's client base and a marked increase in project engagements within a short period. - Leadership in Data Analysis and Consulting: Utilizing comprehensive R and Python data analyses to deliver critical insights, enhancing our clients' decision-making processes in preclinical development. Key services include high-content imaging analysis, functional genomics (including microarray, xRNA-seq differential gene expression, Over Representation Analysis, Gene Set Enrichment Analysis), pharmacokinetics (ADMET-PK), and pharmacodynamics (PD) interactions. - Company’s Pipeline Innovation: Directing the design and development of a pioneering biomarker-surveillance solution for neurological diseases, by integrating human-centric data with machine-learning-powered technology. This automation system aims to predict disease penetrance and onset age in patients, contributing to the advancement of precision medicine.We welcome you to contact us to learn how we can help you expedite your drug's market entry efficiently and effectively.

Salt Lake City, Utah, Us

South San Francisco, California, Us

•Delivered product differentiation recommendations, biomarker data from fluid and imaging for IND-enabling package by designing and executing translational biomarker strategies (i.e. target engagement,identification of pharmacodynamic-, safety-, and predictive-biomarkers)•Validated in progressing molecules into lead optimization through functional genomics tactics (transcriptomics, proteomics, lipidomics, secretomics), automated HTS enabling technologies (MSD, Simoa, ELISA, Fluidigm), primary mammalian cell culture (human- and NHP- PBMC/macrophage), mammal tissues (brain, CSF, plasma), and biostatistical analysis (R, Prism)•Managed CROs for analytical validation of biomarker assays•Prepared translation-related sections in IND and published biomarker findings in 4 studies (EMBO Mol Med, bioRxiv, Mol Neurodegener, Nat. Neurosci)

London, Greater London, Gb

Ann Arbor, Mi, Us

• Identified the druggability for 3 phenotype modifier genes that affect disease penetrance and expressivity in isolated dystonia by directing collaborative research teams with IBM T.J Watson Research Center and Washington University in St. Louis to drive High- Throughput Imaging screening on CRISPR-modified neurons • Validated Tor1b as gene therapy for dystonia mouse models by designing and executing histopathological and behavioral analyses • Deep understanding of neuronal differentiation, autophagy pathway, ubiquitin–proteasome system, and liver lipid metabolism • Hands-on experience with primary mammalian cell culture (ESC, NSC, MEF, cortical neurons, hippocampal neurons, cerebellar neurons, glia, hepatocytes), CRISPR, microscope technology (TEM, fluorescence), and high-throughput imaging • Published 3 studies in HMG, JCI, eLife

Ann Arbor, Mi, Us

• Discovered disease pathogenesis of dystonia (DYT1 and DYT6), identified proteinopathies (K-ɛ-GG) profiling (collaborated with Genentech), and characterized transcriptomic changes in developmental neurodegenerative movement disorders by generating first-in-class in-vivo models which well mimics human behavioral deficiency, disease onset, and penetrance • Strong understanding of CNS development, ubiquitin–proteasome system, lipid droplets, oligodendrocyte differentiation, and the myelination process • Hands-on experience with in-vivo genetic engineering, histopathologic techniques (IHC, IF, ISH, TUNEL, EdU birth dating), cell differentiation, and microscope technology (Stereology, TEM, fluorescence) • Published 3 studies in JCS, Cell reports, and Developmental Cell

Ann Arbor, Mi, Us

• Discovered autophagy/autophagosome required for self-renewal and differentiation of postnatal neural stem cells through activation of mitophagy • Designed and generated in-vivo murine models for isolated dystonia (DYT1, DYT6) and developmental ventriculomegaly for investigating disease pathogenesis • Detailed knowledge of adult neurogenesis, autophagy/mitophagy process, and neurodegeneration • Hands-on experience with histopathologic techniques (IHC, IF, TUNEL), microscope technology (TEM, fluorescence), neurosphere culture, neural differentiation, and in-vivo genetic engineering (Cre-LoxP approaches) • Published 1 studies in Nature Neuroscience

Ann Arbor, Michigan, Us

• Evaluating and review procedures in animal use protocols for research and training weekly (~5 protocols/week) to ensure compliance with applicable standards, policies, and regulations at the University of Michigan• Approving or withholding approval of initial, renewed, or revised, applications to use animals in research and teaching• Suspending activities not conducted in compliance with federal or university regulations, requirements, and guidelines• Inspecting the university's animal facilities and study areas• Providing continuing training required for personnel working with animals

New York, Ny, Us

• Identified PKA and GSK3β activation primarily mediating developmental neurogenesis under the tissue plasminogen activator and plasminogen proteolytic cascade in fetal alcohol syndromes • Strong understanding of neurogenesis and axonal generation signaling • Hands-on experience with histopathologic techniques (IHC, IF) and in-vivo genetic engineering

Taichung, Tw

• Discovered HGF-induced sustained ERK-activation to promote cell migration and a synergistic crosstalk mechanism in HGF-FAK mediated tumorigenesis • Extensive understanding of cell motility, tumorigenesis, and extracellular matrix-growth factor receptor signaling • Hands-on experience with in-vitro genetic engineering, cell transformation (plasmid transfection, adenoviral transduction), microscope technology (confocal fluorescence, time-lapse), and cellular-function analyses (cytoskeleton-dynamics, trans-well chemotaxis migration and invasion, 3D extracellular matrix in-vitro tumorigenesis) • Published 2 studies in JBC

• Operations officer• Training officer• Intelligence officer (Surrogate)

• Training officer

Taipei, Northern Taiwan, Tw

Department of Agricultural Chemistry, National Taiwan University, Taipei, TaiwanAdvisor: Chia-Yin Lee, Ph.D.• Develop a rapid DNA sequencing technique to identify unknown region of Tn10 gene

Ph.D., Comparative Biomedical Sciences

Second Lieutenant, Infantry Division

B.S., Agricultural Chemistry

Education record